Friedeborg Seitz results 1
· Newest (Page 1/1, per page 25)
Author: Friedeborg Seitz ×Clear All Filters
Search Results
This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 after oral single rising doses (SRDs) or multiple rising doses (MRDs) in healthy volunteers. In the SRD trial (NCT02694354; February 29, 2016), within each of the three dose groups (DGs), six subjects received BI 685509 (1.0, 2.5, or 5.0 mg) and two received placebo ( N = 24). In the MRD trial (NCT03116906; April 17, 2017), withi...
Previous1Next